With increasing global demand for advanced weight loss solutions, Canadian consumers now have a new way to access the recently approved obesity treatment Zepbound. Online pharmacy DutyFreeMeds.com is ...

Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Penn's Kiran Musunuru spoke with The Inquirer about the future of CRISPR technology.

As the global obesity medication market skyrockets, South Korean pharmaceuticals are rushing to develop national obesity drugs. Currently, the global industry is dominated by GLP-1 (glucagon-like ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...

Over half of large US employers plan to cut health benefits in 2026 as rising costs of weight-loss drugs like Wegovy drive up ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...

In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...